A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 996 participants.
Also called NCT07216482
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 996 participants
- Sponsor
- Registry
-
NCT07216482 -
U1111-1319-9502 -
2025-521495-54-00
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Australia, Brazil, Canada, Hungary, Israel, New Zealand, Spain, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT07216482. Randomized; triple masking; primary purpose treatment. Start 2025-11-11 (actual); primary completion 2026-08-03 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
- Condition
- Hyperlipidemia
- Intervention (Drug)
- Enlicitide
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo for Enlicitide
- Intervention (Drug)
- Placebo for Rosuvastatin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct07216482- Content hash
2421b71118aa60a1d11c3d3be75368827349750c71a7e4313bc8c1a170d99a57